Showing posts with label bacterial fatty acid biosynthesis inhibition (FabI inhibitors). Show all posts
Showing posts with label bacterial fatty acid biosynthesis inhibition (FabI inhibitors). Show all posts
Monday, April 8, 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

›
We know that,  AFN-1252, is a selective inhibitor of Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI), which is involved ...